Identification of a Highly Antigenic Linear B Cell Epitope within Plasmodium vivax Apical Membrane Antigen 1 (AMA-1)

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Bueno, Lilian Lacerda ^a   Lobo, Francisco Pereira ^a   Morais, Cristiane Guimarães ^a   Mourão, Luíza Carvalho ^a   de Ávila, Ricardo Andrez Machado ^a   Soares, Irene Silva ^b   Fontes, Cor Jesus ^c   Lacerda, Marcus Vinícius ^d   Olórtegui, Carlos Chavez ^a   Bartholomeu, Daniella Castanheira ^a,f   Fujiwara, Ricardo Toshio ^a,e,g   Braga, Érika Martins ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF MATO GROSSO   (Brazil)

^d Fundacao de Medicina Tropical Dr Heitor Vieira Dourado   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

^f Instituto Nacional de Ciência e Tecnologia Informação Pecuária   (Brazil)

^g Instituto de Ciências da Saúde   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; EPITOPE; IMMUNOGLOBULIN G; MALARIA VACCINE; SYNTHETIC PEPTIDE; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; PARASITE ANTIGEN; PEPTIDE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY;

ADULT; AMINO ACID SEQUENCE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; PARASITE IMMUNITY; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; ADOLESCENT; AGED; ANIMAL; BLOOD; CYTOLOGY; GENETICS; IMMUNOLOGY; MICROBIOLOGY; MIDDLE AGED; MOLECULAR GENETICS;

PLASMODIUM VIVAX;

ADOLESCENT; ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; EPITOPES, B-LYMPHOCYTE; HUMANS; MALARIA, VIVAX; MEMBRANE PROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 79959368460     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0021289     Document Type: Article

References (70)

1. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, et al. (2011) A research agenda to underpin malaria eradication. PLoS medicine 8: e1000406.
2. Richie TL, Saul A, (2002) Progress and challenges for malaria vaccines. Nature 415: 694-701.
3. Anstey NM, Russell B, Yeo TW, Price RN, (2009) The pathophysiology of vivax malaria. Trends Parasitol 25: 220-227.
4. Tan LK, Yacoub S, Scott S, Bhagani S, Jacobs M, (2008) Acute lung injury and other serious complications of Plasmodium vivax malaria. Lancet Infect Dis 8: 449-454.
5. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, et al. (2007) Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77: 79-87.
6. Baird JK, (2004) Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075-4083.
7. Arias AE, Corredor A, (1989) Low response of Colombian strains of Plasmodium vivax to classical antimalarial therapy. Trop Med Parasitol 40: 21-23.
8. Good MF, (2005) Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol 21: 29-34.
9. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA, et al. (2002) Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961-6967.
10. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, et al. (1998) Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 16: 240-247.
11. Herrera S, Corradin G, Arevalo-Herrera M, (2007) An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 23: 122-128.
12. Vekemans J, Ballou WR, (2008) Plasmodium falciparum malaria vaccines in development. Expert Rev Vaccines 7: 223-240.
13. Mahanty S, Saul A, Miller LH, (2003) Progress in the development of recombinant and synthetic blood-stage malaria vaccines. J Exp Biol 206: 3781-3788.
14. Morais CG, Soares IS, Carvalho LH, Fontes CJ, Krettli AU, et al. (2006) Antibodies to Plasmodium vivax apical membrane antigen 1: persistence and correlation with malaria transmission intensity. Am J Trop Med Hyg 75: 582-587.
15. Udhayakumar V, Kariuki S, Kolczack M, Girma M, Roberts JM, et al. (2001) Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII. Am J Trop Med Hyg 65: 100-107.
16. Thomas AW, Trape JF, Rogier C, Gonçalves A, Rosário VE, et al. (1994) High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83/AMA-1) as detected by capture-enzyme linked immunosorbent assay using full-length baculovirus recombinant PF83/AMA-1. Am J Trop Med Hyg 51: 730-740.
17. Remarque EJ, Faber BW, Kocken CH, Thomas AW, (2008) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
18. Hodder AN, Crewther PE, Anders RF, (2001) Specificity of the protective antibody response to apical membrane antigen 1. Infect Immun 69: 3286-3294.
19. Peterson MG, Marshall VM, Smythe JA, Crewther PE, Lew A, et al. (1989) Integral membrane protein located in the apical complex of Plasmodium falciparum. Mol Cell Biol 9: 3151-3154.
20. Narum DL, Thomas AW, (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol Biochem Parasitol 67: 59-68.
21. Howell SA, Well I, Fleck SL, Kettleborough C, Collins CR, et al. (2003) A single malaria merozoite serine protease mediates shedding of multiple surface proteins by juxtamembrane cleavage. J Biol Chem 278: 23890-23898.
22. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ, (2001) Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J Biol Chem 276: 31311-31320.
23. Donahue CG, Carruthers VB, Gilk SD, Ward GE, (2000) The Toxoplasma homolog of Plasmodium apical membrane antigen-1 (AMA-1) is a microneme protein secreted in response to elevated intracellular calcium levels. Mol Biochem Parasitol 111: 15-30.
24. Gaffar FR, Yatsuda AP, Franssen FF, de Vries E, (2004) Erythrocyte invasion by Babesia bovis merozoites is inhibited by polyclonal antisera directed against peptides derived from a homologue of Plasmodium falciparum apical membrane antigen 1. Infect Immun 72: 2947-2955.
25. Waters AP, Thomas AW, Deans JA, Mitchell GH, Hudson DE, et al. (1990) A merozoite receptor protein from Plasmodium knowlesi is highly conserved and distributed throughout Plasmodium. J Biol Chem 265: 17974-17979.
26. Hehl AB, Lekutis C, Grigg ME, Bradley PJ, Dubremetz JF, et al. (2000) Toxoplasma gondii homologue of plasmodium apical membrane antigen 1 is involved in invasion of host cells. Infect Immun 68: 7078-7086.
27. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol 38: 706-718.
28. Li F, Dluzewski A, Coley AM, Thomas A, Tilley L, et al. (2002) Phage-displayed peptides bind to the malarial protein apical membrane antigen-1 and inhibit the merozoite invasion of host erythrocytes. J Biol Chem 277: 50303-50310.
29. Mitchell GH, Thomas AW, Margos G, Dluzewski AR, Bannister LH, (2004) Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells. Infect Immun 72: 154-158.
30. Fraser TS, Kappe SH, Narum DL, VanBuskirk KM, Adams JH, (2001) Erythrocyte-binding activity of Plasmodium yoelii apical membrane antigen-1 expressed on the surface of transfected COS-7 cells. Mol Biochem Parasitol 117: 49-59.
31. Kato K, Mayer DC, Singh S, Reid M, Miller LH, (2005) Domain III of Plasmodium falciparum apical membrane antigen 1 binds to the erythrocyte membrane protein Kx. Proc Natl Acad Sci U S A 102: 5552-5557.
32. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, et al. (2004) A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490-9496.
33. Putaporntip C, Jongwutiwes S, Grynberg P, Cui L, Hughes AL, (2009) Nucleotide sequence polymorphism at the apical membrane antigen-1 locus reveals population history of Plasmodium vivax in Thailand. Infect Genet Evol 9: 1295-1300.
34. Gunasekera AM, Wickramarachchi T, Neafsey DE, Ganguli I, Perera L, et al. (2007) Genetic diversity and selection at the Plasmodium vivax apical membrane antigen-1 (PvAMA-1) locus in a Sri Lankan population. Mol Biol Evol 24: 939-947.
35. Chesne-Seck ML, Pizarro JC, Vulliez-Le Normand B, Collins CR, Blackman MJ, et al. (2005) Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol Biochem Parasitol 144: 55-67.
36. Lalitha PV, Ware LA, Barbosa A, Dutta S, Moch JK, et al. (2004) Production of the subdomains of the Plasmodium falciparum apical membrane antigen 1 ectodomain and analysis of the immune response. Infect Immun 72: 4464-4470.
37. Mufalo BC, Gentil F, Bargieri DY, Costa FT, Rodrigues MM, et al. (2008) Plasmodium vivax apical membrane antigen-1: comparative recognition of different domains by antibodies induced during natural human infection. Microbes Infect 10: 1266-1273.
38. Kimura M, Kaneko O, Liu Q, Zhou M, Kawamoto F, et al. (1997) Identification of the four species of human malaria parasites by nested PCR that targets variant sequences in the small subunit rRNA gene. Parasitology International 46: 91-95.
39. Rodrigues MH, Rodrigues KM, Oliveira TR, Comodo AN, Rodrigues MM, et al. (2005) Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1. Int J Parasitol 35: 185-192.
40. Kocken CH, Dubbeld MA, Van Der Wel A, Pronk JT, Waters AP, et al. (1999) High-level expression of Plasmodium vivax apical membrane antigen 1 (AMA-1) in Pichia pastoris: strong immunogenicity in Macaca mulatta immunized with P. vivax AMA-1 and adjuvant SBAS2. Infect Immun 67: 43-49.
41. Larsen JE, Lund O, Nielsen M, (2006) Improved method for predicting linear B-cell epitopes. Immunome Res 2: 2.
42. Dosztanyi Z, Csizmok V, Tompa P, Simon I, (2005) IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21: 3433-3434.
43. Gausepohl H, Boulin C, Kraft M, Frank RW, (1992) Automated multiple peptide synthesis. Pept Res 5: 315-320.
44. Morais CG, (2005) Resposta humoral de isotipos de IgG às proteínas MSP-119 e AMA-1 de Plasmodium vivax em indivíduos expostos a diferentes situações de transmissão de malária no Brasil Belo Horizonte Universidade Federal de Minas Gerais.
45. Santiago HC, Bennuru S, Boyd A, Eberhard M, Nutman TB, (2011) Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis. The Journal of allergy and clinical immunology 127: 479-486.
46. Moorthy VS, Good MF, Hill AV, (2004) Malaria vaccine developments. Lancet 363: 150-156.
47. Wykes M, Good MF, (2007) A case for whole-parasite malaria vaccines. Int J Parasitol 37: 705-712.
48. Webster D, Hill AV, (2003) Progress with new malaria vaccines. Bull World Health Organ 81: 902-909.
49. Arevalo-Herrera M, Chitnis C, Herrera S, (2010) Current status of Plasmodium vivax vaccine. Human vaccines 6: 124-132.
50. Deans JA, Knight AM, Jean WC, Waters AP, Cohen S, et al. (1988) Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol 10: 535-552.
51. Collins WE, Pye D, Crewther PE, Vandenberg KL, Galland GG, et al. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 51: 711-719.
52. Narum DL, Ogun SA, Thomas AW, Holder AA, (2000) Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 68: 2899-2906.
53. Saul A, Lawrence G, Allworth A, Elliott S, Anderson K, et al. (2005) A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 23: 3076-3083.
54. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, et al. (1998) Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177: 1664-1673.
55. Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, et al. (2005) Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect Immun 73: 3677-3685.
56. Good MF, Doolan DL, (2010) Malaria vaccine design: immunological considerations. Immunity 33: 555-566.
57. Richards JS, Beeson JG, (2009) The future for blood-stage vaccines against malaria. Immunol Cell Biol 87: 377-390.
58. Angov E, Hillier CJ, Kincaid RL, Lyon JA, (2008) Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One 3: e2189.
59. Feng ZP, Keizer DW, Stevenson RA, Yao S, Babon JJ, et al. (2005) Structure and inter-domain interactions of domain II from the blood-stage malarial protein, apical membrane antigen 1. J Mol Biol 350: 641-656.
60. Oliveira-Ferreira J, Lacerda MV, Brasil P, Ladislau JL, Tauil PL, et al. (2010) Malaria in Brazil: an overview. Malar J 9: 115.
61. Druilhe P, Khusmith S, (1987) Epidemiological correlation between levels of antibodies promoting merozoite phagocytosis of Plasmodium falciparum and malaria-immune status. Infect Immun 55: 888-891.
62. Carlton JM, Adams JH, Silva JC, Bidwell SL, Lorenzi H, et al. (2008) Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature 455: 757-763.
63. Pain A, Hertz-Fowler C, (2009) Plasmodium genomics: latest milestone. Nat Rev Microbiol 7: 180-181.
64. Wastling JM, Xia D, Sohal A, Chaussepied M, Pain A, et al. (2009) Proteomes and transcriptomes of the Apicomplexa-where's the message? Int J Parasitol 39: 135-143.
65. Bozdech Z, Mok S, Hu G, Imwong M, Jaidee A, et al. (2008) The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci U S A 105: 16290-16295.
66. Blythe MJ, Flower DR, (2005) Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci 14: 246-248.
67. Doolan DL, (2010) Plasmodium immunomics. Int J Parasitol 41: 3-20.
68. List C, Qi W, Maag E, Gottstein B, Muller N, et al. (2010) Serodiagnosis of Echinococcus spp. infection: explorative selection of diagnostic antigens by peptide microarray. PLoS Negl Trop Dis 4: e771.
69. Pizarro JC, Vulliez-Le Normand B, Chesne-Seck ML, Collins CR, Withers-Martinez C, et al. (2005) Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308: 408-411.
70. Gentil F, Bargieri DY, Leite JA, Francoso KS, Patricio MB, et al. (2010) A recombinant vaccine based on domain II of Plasmodium vivax Apical Membrane Antigen 1 induces high antibody titres in mice. Vaccine 28: 6183-6190.